MYGN earnings analysis
What we found in MYGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2.3% year-over-year but missed consensus estimates. The company also faced a net loss of $34.1 million, translating to a diluted EPS of $-0.36, exacerbated by goodwill impairment charges. Overall, management reaffirmed its guidance for full-year revenue of $860 - $880 million, highlighting growth in key segments despite ongoing operating losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Annual Revenue Growth
- Q1 2026 revenue increased 2.3% from $195.9 million in Q1 2025 to $200.4 million.
- Mental Health Segment Growth
- Mental Health segment revenue rose by $7.3 million, a 23.5% increase from $31.0 million in the prior year.
- Gross Margin Improvement
- Gross margin improved slightly to 68.7% in Q1 2026 from 68.5% in Q1 2025.
- Lower Operating Expense Ratio
- General and administrative expenses decreased, leading to a reduction from 33.9% to 31.0% of total revenue.
- Maintained Full-Year Guidance
- Management reiterated full-year revenue guidance of $860-$880 million, unchanged from prior expectations.
- Stable Cancer Care Revenue
- Cancer Care Continuum revenue grew $4.6 million year-over-year despite an 8% decrease in revenue per test.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Net Loss
- Q1 2026 net loss increased to $34.1 million compared to $31.1 million in Q1 2025.
- Goodwill Impairment Charges
- Recorded $5.4 million in goodwill and intangible asset impairment charges.
- Heavy Interest Expense Growth
- Other expense net rose by $3.0 million to $(3.4) million due to increased interest expenses from debt.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.36
- Gross margin
- 68.7%
- Segment
- Cancer Care Continuum: $120.2 million
- Segment
- Prenatal Health: $41.9 million
- Segment
- Mental Health: $38.3 million
What they said about what is next.
Management confirmed full year 2026 revenue guidance.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 24, 2026
- Myriad describes a strategy focused on the Cancer Care Continuum, Prenatal Health and Mental Health, leveraging its legacy hereditary-cancer leadership, new partnerships (PATHOMIQ, SOPHiA GENETICS) and next‑generation…
- 10-Q · November 4, 2025
- Myriad reported Q3 2025 revenue of $205.7M (down $7.6M vs. $213.3M in Q3 2024) and a GAAP net loss of $27.4M (EPS $(0.29)). Results show sequential operating and EPS recovery from the Q2 2025 impairment quarter, but…
- 10-Q · August 6, 2025
- Myriad reported Q2 revenue of $213.1M (vs $211.5M a year ago) but recorded $316.7M of goodwill and long‑lived asset impairment charges driving an operating loss of $329.2M and a net loss of $330.5M (EPS $(3.57)).…
- 10-Q · May 7, 2025
- Myriad reported Q1 2025 revenue of $195.9 million, down from $202.2 million in Q1 2024, with gross profit of $134.2 million (~68.5% gross margin) and an operating loss of $29.0 million (−14.8% margin). The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MYGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever